First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Adenosine
CD73
Monoclonal antibody
Oleclumab
Tumor microenvironment
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
02
11
2022
accepted:
19
03
2023
medline:
15
6
2023
pubmed:
5
4
2023
entrez:
4
4
2023
Statut:
ppublish
Résumé
CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC). Patients received oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg intravenously Q2W. 192 patients were enrolled, 66 during escalation and 126 (42 CRC, 42 PDAC, 42 NSCLC) during expansion. No dose-limiting toxicities occurred during escalation. In the monotherapy and combination therapy escalation cohorts, treatment-related adverse events (TRAEs) occurred in 55 and 54%, respectively, the most common being fatigue (17 and 25%). In the CRC, PDAC, and NSCLC expansion cohorts, 60, 57, and 45% of patients had TRAEs, respectively; the most common were fatigue (15%), diarrhea (9%), and rash (7%). Free soluble CD73 and CD73 expression on peripheral T cells and tumor cells showed sustained decreases, accompanied by reduced CD73 enzymatic activity in tumor cells. Objective response rate during escalation was 0%. Response rates in the CRC, PDAC, and NSCLC expansion cohorts were 2.4% (1 complete response [CR]), 4.8% (1 CR, 1 partial response [PR]), and 9.5% (4 PRs), respectively; 6-month progression-free survival rates were 5.4, 13.2, and 16.0%. Oleclumab ± durvalumab had a manageable safety profile, with pharmacodynamic activity reflecting oleclumab's mechanism of action. Evidence of antitumor activity was observed in tumor types that are generally immunotherapy resistant. Clinicaltrials.gov, NCT02503774; date of registration, July 17, 2015.
Sections du résumé
BACKGROUND
BACKGROUND
CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC).
METHODS
METHODS
Patients received oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg intravenously Q2W.
RESULTS
RESULTS
192 patients were enrolled, 66 during escalation and 126 (42 CRC, 42 PDAC, 42 NSCLC) during expansion. No dose-limiting toxicities occurred during escalation. In the monotherapy and combination therapy escalation cohorts, treatment-related adverse events (TRAEs) occurred in 55 and 54%, respectively, the most common being fatigue (17 and 25%). In the CRC, PDAC, and NSCLC expansion cohorts, 60, 57, and 45% of patients had TRAEs, respectively; the most common were fatigue (15%), diarrhea (9%), and rash (7%). Free soluble CD73 and CD73 expression on peripheral T cells and tumor cells showed sustained decreases, accompanied by reduced CD73 enzymatic activity in tumor cells. Objective response rate during escalation was 0%. Response rates in the CRC, PDAC, and NSCLC expansion cohorts were 2.4% (1 complete response [CR]), 4.8% (1 CR, 1 partial response [PR]), and 9.5% (4 PRs), respectively; 6-month progression-free survival rates were 5.4, 13.2, and 16.0%.
CONCLUSIONS
CONCLUSIONS
Oleclumab ± durvalumab had a manageable safety profile, with pharmacodynamic activity reflecting oleclumab's mechanism of action. Evidence of antitumor activity was observed in tumor types that are generally immunotherapy resistant.
CLINICAL TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov, NCT02503774; date of registration, July 17, 2015.
Identifiants
pubmed: 37016126
doi: 10.1007/s00262-023-03430-6
pii: 10.1007/s00262-023-03430-6
pmc: PMC10264501
doi:
Substances chimiques
durvalumab
28X28X9OKV
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Banques de données
ClinicalTrials.gov
['NCT02503774']
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2443-2458Informations de copyright
© 2023. The Author(s).
Références
Trends Immunol. 2012 May;33(5):231-7
pubmed: 22487321
JCI Insight. 2022 Feb 8;7(3):
pubmed: 35132961
Curr Opin Pharmacol. 2020 Aug;53:66-76
pubmed: 32777746
Front Immunol. 2017 Nov 14;8:1526
pubmed: 29184552
Oncoimmunology. 2016 Jul 11;5(8):e1208875
pubmed: 27622077
Cancer Immunol Res. 2023 Jan 3;11(1):56-71
pubmed: 36409930
Eur J Cancer. 2020 Mar;128:119-128
pubmed: 32037060
JAMA Oncol. 2019 Oct 01;5(10):1431-1438
pubmed: 31318392
Expert Opin Biol Ther. 2019 Sep;19(9):927-935
pubmed: 31272242
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Cancer Res. 2013 Oct 15;19(20):5626-35
pubmed: 23983257
Pancreatology. 2021 Aug;21(5):942-949
pubmed: 33832821
Int J Cancer. 2018 Sep 15;143(6):1494-1504
pubmed: 29663369
MAbs. 2016;8(3):454-67
pubmed: 26854859
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32238470
Cancer Immunol Immunother. 2021 Jul;70(7):1965-1976
pubmed: 33416944
Front Pharmacol. 2020 Nov 16;11:609931
pubmed: 33364969
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
J Clin Oncol. 2022 Oct 10;40(29):3383-3393
pubmed: 35452273
Cell Rep. 2019 May 21;27(8):2411-2425.e9
pubmed: 31116985
Support Care Cancer. 2020 Dec;28(12):6111-6117
pubmed: 32857220
Front Immunol. 2020 Apr 15;11:508
pubmed: 32351498
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2097-103
pubmed: 22772752
Oncoimmunology. 2020 Apr 23;9(1):1746138
pubmed: 32363113
Oncogene. 2022 Feb;41(7):971-982
pubmed: 35001076
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629
pubmed: 32514148
J Biophys Biochem Cytol. 1955 Nov 25;1(6):483-8
pubmed: 13278361
Expert Opin Drug Saf. 2020 Jun;19(6):653-659
pubmed: 32357806
Br J Cancer. 2022 May;126(9):1329-1338
pubmed: 34980880
Cancers (Basel). 2021 Jan 07;13(2):
pubmed: 33430239
Cancer Res. 2011 Apr 15;71(8):2892-900
pubmed: 21292811
Biochimie. 2020 Sep;176:21-30
pubmed: 32585229
Oncotarget. 2017 Jan 31;8(5):8738-8751
pubmed: 28060732